Metrics to compare | 006280 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship006280PeersSector | |
|---|---|---|---|---|
P/E Ratio | 9.5x | 8.7x | −0.2x | |
PEG Ratio | 0.05 | 0.08 | 0.00 | |
Price/Book | 1.0x | 1.6x | 2.6x | |
Price / LTM Sales | 0.8x | 3.1x | 2.6x | |
Upside (Analyst Target) | 47.9% | 41.1% | 77.0% | |
Fair Value Upside | Unlock | 27.4% | 13.7% | Unlock |
GC Biopharma Corp., a biopharmaceutical company, develops and sells pharmaceutical drugs in South Korea and internationally. It provides over-the-counter drugs, such as Acustop Cataplasma for Analgesic and anti-inflammatory effect; and Kenhancer plaster for anti-inflammatory. The company also offers prescription drugs such as Hunterase ICV for treatment for hunter syndrome effect; Hunterase for treatment for hunter syndrome; vaccines include BARYCELA Inj. for prophylaxis of varicella; GC FLU Quadrivalent Pre-filled syringe inj. for prevention of influenza(flu); and GC FLU pre-filled syringe inj. for prevention of influenza(flu). In addition, it offers plasma derivatives such as Alyglo for treatment of primary humoral immunodeficiency in adults, Sero-Tet inj. (Hyper-Tet inj.) for the prophylaxis of tetanus and the reduction of tetanus symptoms, Hepabig inj. for prevention of hepatitis B, I.V. Hepabig inj. for prevention of hepatitis B recurrence in patients following liver transplantation, Green-VIII inj for the treatment of Hemophilia A with supplies of blood coagulation factor VIII, Albumin inj.-GCC for hypoalbuminemia and shock in acute hemorrhage, as well as low synthesis of albumin, and I.V.-Globulin SN inj. 5% for including high purity IgG immune function improved formulation; and provides CMO services. The company was founded in 1967 and is headquartered in Yongin-Si, South Korea. GC Biopharma Corp. operates as a subsidiary of Green Cross Holdings Corporation.